FDA Brief

Warning letters Drugs

FDA warning letter to

Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi

High riskIssued Nov 13, 2023Posted Dec 26, 2023Center for Drug Evaluation and Research | CDER

FDA warns Turkish hand sanitizer maker Sudesan of CGMP violations and adulterated drugs.

What happened

FDA reviewed records Sudesan submitted on March 11, 2022, in response to FDA’s August 26, 2021 request for records under section 704(a)(4) of the FD&C Act for its OTC drug facility. The records showed inadequate identity testing of incoming components, inadequate identity and strength testing of finished hand sanitizers before release, and insufficient stability data to support expiration dates. FDA placed the firm on Import Alert 66-40 on October 18, 2023.

What FDA found

  1. Sudesan did not show that it tested each incoming component for identity, and it did not validate the reliability of supplier test results; ethanol lot testing began after the drugs were shipped to the U.S.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. Sudesan did not provide evidence that it tested each finished hand sanitizer batch for identity and strength of the active ingredient before release; certificates of analysis showed only appearance, odor, density, and pH testing.

    21 CFR 211.165(a)
  3. Sudesan’s stability data covered only 12 weeks and only products made in 2019, so it did not support the expiration dates assigned to its hand sanitizer drug products.

    21 CFR 211.166(a)

What FDA wants

FDA tells Sudesan to correct the violations and respond in writing within 15 working days with corrective actions, including independent reviews and testing plans; if it cannot complete the actions in that time, it must state why and provide a completion schedule.

Who should pay attention

  • brands and distributors selling Sudesan hand sanitizer in the U.S.
  • drug manufacturers that buy ethanol or other components relying on supplier certificates
  • contract manufacturers and importers of OTC drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk